Vireo Growth Inc. (OTCQX: VREOF) has initiated coverage as a notable player in the cannabis industry, targeting a price of $1.50 per share over the next 12 months. This forecast suggests a considerable upside from the current stock price, reflecting the company’s strategic growth plans following several recent acquisitions.
Vireo Growth operates as a vertically-integrated multi-state operator (MSO) in the cannabis sector. The company cultivates, produces, and distributes a diverse range of medical and recreational cannabis products through its own retail locations and third-party dispensaries across six states, including established markets like Maryland, Minnesota, and New York.
Key to Vireo’s growth strategy are its recent acquisitions of Wholesome in Utah, Proper Brands in Missouri, and Deep Roots Harvest in Nevada. These deals expand Vireo’s operational footprint to include eight cultivation facilities and 38 dispensaries. Financially, Vireo ranks as the eighth largest publicly traded cannabis company based on projected revenues for 2026, while it stands sixth in terms of adjusted EBITDA, highlighting the importance of scale in the current consolidating market.
The company’s management aims to build a robust network of local operators in financially promising markets. While day-to-day operations remain under independent management, these affiliates can utilize shared corporate services, enhancing their growth potential.
Despite challenges posed by regulatory uncertainties, Vireo Growth is positioned for substantial growth. The U.S. cannabis market generated approximately $32 billion in revenue last year, with ongoing expansion anticipated as more states legalize cannabis and consumer demand increases. Vireo’s growth is expected to primarily stem from Minnesota and New York, where the management is focused on boosting cultivation and production capacities to meet rising adult-use demand.
Following the completion of its recent acquisitions, Vireo has reached a critical mass that allows for greater market share consolidation. The company’s approach to mergers and acquisitions (M&A) involves targeting distressed assets in mature markets that do not overlap with existing operations.
In terms of profitability, projections indicate earnings per share (EPS) of $0.01 for 2025, a notable recovery from a projected loss of $0.16 per share in 2024. This improvement is anticipated to continue with EPS reaching $0.05 in 2026, driven by the integration of recent acquisitions and expected revenue growth, particularly from adult-use sales in Minnesota and New York.
The company expects a significant increase in revenue starting in the latter half of the year, following the completion of the acquisitions. Retailers in states transitioning from medical to recreational sales have reported revenue increases of two to three times, suggesting a similar trend could occur for Vireo.
Key areas for margin expansion include reducing corporate redundancies through the integration of acquired companies, shifting sales towards more profitable recreational products, and maintaining strict expense management.
Vireo’s financial strength sets it apart from many U.S.-based cannabis operators, who often struggle to secure funding due to regulatory constraints. The company recently raised $81 million in gross proceeds from a private placement of shares, which will primarily fund working capital and organic growth initiatives while positioning it for future M&A opportunities.
Vireo’s debt profile is favorable, with long-term maturities and significant credit facilities. After accounting for income taxes and liabilities, the company’s pro forma net leverage is at $61 million, or 0.9 times its projected adjusted EBITDA for 2025, which is low compared to industry peers.
The estimated price target of $1.50 per share indicates substantial upside potential as the market adjusts to Vireo’s improving fundamentals. As integration of the latest acquisitions progresses, investor confidence is expected to rise, potentially driving a reassessment of the stock’s value. Additionally, favorable changes in regulatory environments, such as federal rescheduling and further state legalizations, could serve as catalysts for Vireo’s growth.
Comparative analysis shows that similar cannabis stocks are currently trading at an average enterprise value-to-EBITDA multiple of around six times based on 2025 projections. Vireo’s current enterprise value is approximately $480 million, translating to 3.5 times its adjusted EBITDA forecast for 2026. This suggests significant potential for stock appreciation should Vireo’s shares begin to trade at industry-standard multiples.
Spanish 
English 
German 
Czech